# Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study

> **NCT01668667** · PHASE4 · COMPLETED · sponsor: **XenoPort, Inc.** · enrollment: 501 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** GSK1838262 600 mg
- **DRUG:** GSK1838262 450 mg
- **DRUG:** GSK1838262 300 mg
- **DRUG:** GSK1838262 Placebo match

## Key facts

- **NCT ID:** NCT01668667
- **Lead sponsor:** XenoPort, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 501 (ACTUAL)
- **Last updated:** 2021-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01668667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01668667, "Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01668667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*